@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw> .
@prefix sub: <http://purl.org/np/RABcRpOHyn4H1Diy-Z2kNeE1PCnb7Rftlr36D_RVYxIcw#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_9538> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_9538> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB09331> ;
    a rdf:Statement ;
    rdfs:label "darzalex is indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent darzalex is a cd38 directed cytolytic antibody indicated in combination with bortezomib melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor as monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor pi and an immunomodulatory agent or who are double refractory to a pi and an immunomodulatory agent 1" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB09331> bl:category bl:Drug .
}
sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "W87Ykj7wWgb+O9M9lwPLu9faZ7KvyGzXMiu4hbMaA5rdWBehXMCMQ9oXYRJ7cWQ1MrWpUajUnIu6iy7dpDV9AtwDBPD9Cz1CdIa3gbK1YUUv9CMbgFI0HrMJoqrX6xYdw3CXa92s7QqIUROH/gzk3j5Dibk3YEGR8AhiNX8OezA=" ;
    npx:hasSignatureTarget this: .
  this: dc1:created "2021-06-12T12:46:02.775+02:00"^^xsd:dateTime ;
    dc1:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}